Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders

Omega Funds is sole investor for Swiss start-up’s series A, reuniting firm with CEO Plitz 

By stephen hansen, associate editor
October 13, 2020 9:50 PM UTC

Swiss newco Chord launched with $16 million to develop an established multiple sclerosis drug in orphan autoimmune indications in a deal that reunites Omega Funds with former Wilson CSO Tom Plitz. 

Omega Funds was the sole investor in the series A round for Chord Therapeutics, which is developing a single asset, CRD1, to treat neuromyelitis optica spectrum disorder (NMOSD) and a second orphan indication, myasthenia gravis (MG). CRD1 is an oral formulation of cladribine, a purine nucleoside analog. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Chord Therapeutics S.a.r.l.